Atara Biotherapeutics (United States)
- World rank, 2022–2025
- #12,674 of 28,054 · #26,892 all time
- Rank in United States
- #1,744 of 4,192
- Research works
- 125 ▲ 916% vs 2013–17
- Citations
- 1.2k 9.2 per fractional work
- Top-10% rate
- 11.0% record average 16.5%
- Open access
- 44% world 28%
Field profile
Location quotient across every field it publishes in: outside the ring is more than an institution of this size would be expected to publish, inside it is less.
Rings at 0.5×, 1× and 2×. Widest outward: Immunology and Microbiology, 15.9×. Every wedge is a field page.
- Immunology and Microbiology 15.9×
- Biochemistry, Genetics and Molecular Biology 3.9×
- Medicine 2.9×
- Neuroscience 1.8×
- Pharmacology, Toxicology and Pharmaceutics 1.3×
- Economics, Econometrics and Finance 0.8×
- Nursing 0.2×
- Mathematics 0.2×
- Health Professions 0.1×
- Engineering 0.1×
- Environmental Science 0.1×
- Computer Science 0.1×
- Dentistry 0.1×
- Psychology 0.0×
- Materials Science 0.0×
- Agricultural and Biological Sciences 0.0×
Who are the top researchers at Atara Biotherapeutics (United States)?
Ranked on the composite score, Blake T. Aftab, David H. Chu and Arie Barlev lead among researchers whose main affiliation is Atara Biotherapeutics (United States).
- 1 Blake T. Aftab United States · #806,252 worldwide 37 citations · 18 works
- 2 David H. Chu United States · #975,148 worldwide 30 citations · 15 works
- 3 Arie Barlev United States · #1,403,018 worldwide 9 citations · 19 works
Which keywords describe research at Atara Biotherapeutics (United States)?
By fractional works in 2022–2025, weighted toward what it does more of than the world: Cancer Immunotherapy, Lymphoma, Immunotherapy, Tumor Regression, Leukemia, CAR T Cells, Chimeric Antigen Receptor and Glycosylation.
- Recombinant Protein
- Natural Killer Cells
- Multiple Sclerosis
- Diagnostic Criteria
- Tumor Antigen
- Monoclonal Antibody
- Filaggrin
- Dendritic Cells
- TH17 Cells
- Antigen Presentation
- Autoantibodies
- Regulatory T Cells
- Immune System
- TGF-ß
- Antibody Engineering
- Epidemiology
- Glycosylation
- CAR T Cells
- Tumor Regression
- Lymphoma
- Cancer Immunotherapy
- Immunotherapy
- Leukemia
- Chimeric Antigen Receptor
- Monoclonal Antibodies
- Therapeutic Antibodies
- Fc Receptors
- Innate Immunity
- Immunity
- Diagnosis
- Rituximab
- IL-17
- Immunosuppressive Therapy
- Cell Signaling
- Immune Dysregulation
- Skin Microbiome
- Vaccine Adjuvants
- Gene Therapy
- NK Cell Recognition
- Mammalian Cells
Size is fractional works in 2022–2025 in the topics tagged with each word; colour is the word's share of this institution's work against its share of the world's. The 40 words are chosen for being large and distinctive. Each links to the topic it comes from most.
All 40 words, with their numbers
- Cancer Immunotherapy10▲ 101×3 topics
- Lymphoma9▲ 86×3 topics
- Immunotherapy9▲ 19×5 topics
- Tumor Regression8▲ 113×2 topics
- Leukemia8▲ 145×2 topics
- CAR T Cells8▲ 160×1 topic
- Chimeric Antigen Receptor8▲ 160×1 topic
- Glycosylation6▲ 78×3 topics
- Monoclonal Antibodies4▲ 70×3 topics
- Epidemiology4▲ 1.57×19 topics
- Therapeutic Antibodies4▲ 82×2 topics
- Antibody Engineering4▲ 99×1 topic
- Fc Receptors4▲ 99×1 topic
- TGF-ß4▲ 35×3 topics
- Innate Immunity3▲ 15×4 topics
- Immune System3▲ 19×3 topics
- Immunity3▲ 11×4 topics
- Regulatory T Cells3▲ 36×3 topics
- Diagnosis3▲ 4.2×6 topics
- Autoantibodies3▲ 16×3 topics
- Rituximab3▲ 25×3 topics
- Antigen Presentation2▲ 42×2 topics
- IL-172▲ 111×1 topic
- TH17 Cells2▲ 111×1 topic
- Immunosuppressive Therapy2▲ 18×4 topics
- Dendritic Cells2▲ 35×2 topics
- Cell Signaling2▲ 20×5 topics
- Filaggrin2▲ 59×1 topic
- Immune Dysregulation2▲ 38×2 topics
- Monoclonal Antibody2▲ 57×2 topics
- Skin Microbiome2▲ 59×1 topic
- Tumor Antigen2▲ 49×1 topic
- Vaccine Adjuvants2▲ 49×1 topic
- Diagnostic Criteria2▲ 12×1 topic
- Gene Therapy2▲ 14×3 topics
- Multiple Sclerosis2▲ 70×1 topic
- NK Cell Recognition2▲ 39×1 topic
- Natural Killer Cells2▲ 39×1 topic
- Mammalian Cells2▲ 106×1 topic
- Recombinant Protein2▲ 106×1 topic
Which research topics does Atara Biotherapeutics (United States) publish most on?
By volume in 2022–2025: CAR-T cell therapy research, Monoclonal and Polyclonal Antibodies Research, Psoriasis: Treatment and Pathogenesis and Immunotherapy and Immune Responses.
Area is fractional works; colour is the subfield each topic belongs to.
- 1 CAR-T cell therapy research Oncology 8 works
- 2 Monoclonal and Polyclonal Antibodies Research Radiology, Nuclear Medicine and Imaging 4 works
- 3 Psoriasis: Treatment and Pathogenesis Immunology 2 works
- 4 Immunotherapy and Immune Responses Immunology 2 works
- 5 Dermatology and Skin Diseases Dermatology 2 works
- 6 Immune Cell Function and Interaction Immunology 2 works
- 7 Multiple Sclerosis Research Studies Pathology and Forensic Medicine 2 works
- 8 Viral Infectious Diseases and Gene Expression in Insects Molecular Biology 2 works
- 9 Cancer Immunotherapy and Biomarkers Oncology 2 works
- 10 Viral-associated cancers and disorders Oncology 1 works
How open and international is its research?
Against the world’s own shares — the tick on each track. Both are shares of its output, so they sit on one scale and can be read against each other as well as against the world.
World: 28% of research is openly available.
World: 19% is written across borders.
How has Atara Biotherapeutics (United States)'s research output changed?
Output in 2018–2022 was 916% higher than in 2013–2017.
The same series as a ribbon — one cell per year, darker for more. The line above answers how much; this answers when.
Other research institutions in South San Francisco
- Sunesis (United States)
- Exelixis (United States)
- Kaiser Permanente South San Francisco Medical Center
- Cytokinetics (United States)
- Portola Pharmaceuticals (United States)
- NGM Biopharmaceuticals (United States)
- Rapt Therapeutics (United States)
- Fluidigm (United States)
Research measures only: rankings here say nothing about teaching, admissions or student experience. Comparable institutions and collaboration partners are in the interactive view on the map.